Clinician-to-Clinician Update Clinician-to-Clinician Update

Cancer Care Specialty Updates

October 2016

Oct-2016-Consult-Specialty-Updates-Feature-Image-Hui Jane 1396186078 MH Bio
— Jane Hui, MD, MS

Surgical oncologist joins M Health team

Surgeon Jane Hui MD, MS, joins University of Minnesota Health Cancer Care as a specialist focusing on breast cancer, melanoma, and sarcoma. She completed her medical degree and general surgery residency at Queen’s University in Kingston, Ontario, and recently held a Complex General Surgery Surgical Oncology Fellowship at Fox Chase Cancer Center and Temple University. Hui also holds a Master’s in Clinical Research for Health Professionals from Drexel University in Philadelphia.

New system improves radiation therapy delivery

A new system available at University of Minnesota Health Radiation Oncology Clinics aids in the precision and delivery of radiation therapy. The patient’s breathing or other subtle movements can cause radiation therapy to miss its target areas and otherwise diminish treatment effectiveness. During delivery of radiation therapy, the C-Rad system enables real-time and continuous tracking of any motion of the patient’s skin, without requiring the presence of markers or tattoos. The system’s tracking allows immediate detection of any setup errors and provides information on any movement during treatment delivery.

Examining cardiovascular disease risk in breast cancer survivors

A new study sheds light on a breast cancer therapy’s link to increased risk of cardiovascular disease. Aromatase inhibitors (AIs), an effective treatment for estrogen receptor-positive breast cancer, have been associated with higher rates of hypertension, hypercholesterolemia, angina pectoris, and ischemic cardiovascular disease. In a crosssectional study of breast cancer survivors conducted by University of Minnesota Health hematologist/oncologist Anne Blaes, MD, postmenopausal women on AIs showed reductions in endothelial function, a predictor of cardiovascular disease. Given AI’s role in reducing recurrence of a prevalent form of breast cancer and the trend toward longer-duration endocrine therapy, the researchers called for further work to confirm these findings.

Related Articles

October 2016

Speeding the Development of Breast Cancer Therapies

A new clinical trial model draws on a database of multisite study findings to advance the discovery of new therapies. The approach is beginning to identify new drugs for difficult to treat breast cancers.

Continue reading

October 2016

Experimental Therapy Aids Patient with Triple-Negative Breast Cancer

A novel drug combined with standard-of-care chemotherapy provides a successful outcome for a clinical trial participant. The drug therapy is being further evaluated in a phase III trial.

Continue reading